MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype
Authors:
- Timothy F. BurnsTBTimothy F. Burns
- Sanja DacicSDSanja Dacic
- Anish ChakkaACAnish Chakka
- Ethan MillerEMEthan Miller
- Maria A. VelezMVMaria A. Velez
- Ashwin SomasundaramASAshwin Somasundaram
- Saveri BhattacharyaSBSaveri Bhattacharya
- Autumn Gaither-DavisAGAutumn Gaither-Davis
- Princey DevadassanPDPrincey Devadassan
- Jingxiao JinJJJingxiao Jin
- Vinod KumarVKVinod Kumar
- Arjun PennathurAPArjun Pennathur
Open Access
- 18 December 2025
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (4)
Abstract
Non–small cell lung cancer exhibits the highest rates of brain metastases (BMs) among all solid tumors, presenting a major clinical challenge. The development of novel therapeutic strategies targeting BMs is clearly needed. We identified a significant enrichment of MET amplification in lung adenocarcinoma (LUAD) BMs compared with primary LUAD and extracranial metastases in oncogene driver–negative patients. Of note, MET -amplified BMs were responsive to MET inhibitors in vivo, including models with acquired MET amplification at the time of metastasis. MET alterations (amplifications and/or mutations) were also more frequently detected in circulating tumor DNA from patients with LUAD BMs than in those without BMs. MET- altered BMs also demonstrated unique genomic features compared with non– MET- altered BMs. Transcriptomic analyses revealed that in contrast to MET WT BMs, MET -amplified BMs exhibited a more inflamed tumor microenvironment and displayed evidence of metabolic adaptation, particularly a reliance on glycolysis in contrast to OXPHOS in MET WT BMs. Furthermore, MET -amplified BMs demonstrated evidence of epithelial-mesenchymal transition signaling, including increased expression of TWIST1. Patients with MET -amplified BMs had significantly shorter overall survival. These findings highlight MET amplification as a critical driver of LUAD BMs, emphasizing its potential as a therapeutic target.Keywords
Funding Information
- National Cancer Institute of the National Institutes of Health (P50CA090440)
- American Cancer Society Research Scholar Award (RSG TBG - 132939)
- The University of Pittsburgh Institute for Precision Medicine (No number)
- Libby’s Lungs (No number)
- We Wish Foundation (No number)
- National Cancer Institute of the National Institutes of Health (P30CA047904)
- National Cancer Institute of the National Institutes of Health (R01 CA244270-01A1)
- U.S. Department of Defense (W81XWH-22-1-0350)
This publication has 114 references indexed in Scilit:
- Astrocytes Upregulate Survival Genes in Tumor Cells and Induce Protection from ChemotherapyNeoplasia, 2011
- Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain MetastasisThe American Journal of Pathology, 2010
- Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung CancersJournal of Thoracic Oncology, 2009
- Met gene copy number predicts the prognosis for completely resected non‐small cell lung cancerCancer Science, 2008
- Hypoxia can induce c‐Met expression in glioma cells and enhance SF/HGF‐induced cell migrationInternational Journal of Cancer, 2007
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Hypoxia-inducible factor-1α correlates with MET and metastasis in node-negative breast cancerBreast Cancer Research and Treatment, 2006
- Hypoxia promotes invasive growth by transcriptional activation of the met protooncogeneCancer Cell, 2003
- Immunohistochemistry with antibodies to hepatocyte growth factor and its receptor protein (c-MET) in human brain tissuesBrain Research, 1994
- Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis.Journal of Clinical Oncology, 1988